MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.00
-4.50
-21.95%
After Hours: 16.49 +0.49 +3.06% 17:55 05/22 EDT
OPEN
17.00
PREV CLOSE
20.50
HIGH
17.50
LOW
15.25
VOLUME
7.12M
TURNOVER
--
52 WEEK HIGH
21.97
52 WEEK LOW
5.35
MARKET CAP
577.52M
P/E (TTM)
-9.0718
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SNDX stock price target is 24.29 with a high estimate of 31.00 and a low estimate of 15.00.

EPS

SNDX News

More
Mid-Afternoon Market Update: NASDAQ Turns Higher; Hewlett Packard Shares Tumble
Toward the end of trading Friday, the Dow traded down 0.14% to 24,440.10 while the NASDAQ rose 0.40% to 9,322.26. The S&P also rose, gaining 0.16% to 9,322.26.
Benzinga · 3d ago
Syndax Pharma's entinostat comes up empty again in breast cancer study
A National Cancer Institute-conducted Phase 3 clinical trial, E2112, evaluating Pfizer's (NYSE:PFE) Aromasin (exemestane), with or without Syndax Pharmaceu
seekingalpha · 3d ago
46 Stocks Moving In Friday's Mid-Day Session
Gainers Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) shares jumped 98.40% to $2.5201 after the company announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study.
Benzinga · 3d ago
Mid-Day Market Update: LiveRamp Surges Following Q4 Results; Syndax Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded down 0.56% to 24338.21 while the NASDAQ fell 0.19% to 9266.93. The S&P also fell, dropping 0.33% to 2938.92.
Benzinga · 3d ago
Syndax Pharmaceuticals Crashes On Late-Stage Failure In Breast Cancer
Investor's Business Daily · 3d ago
FL, HPE among premarket losers
Seeking Alpha - Article · 3d ago
Barclays Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $23
Barclays maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $25 to $23.
Benzinga · 3d ago
30 Stocks Moving in Friday's Pre-Market Session
Gainers Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) shares rose 65.2% to $2.18 in pre-market trading after the company reported results of second interim analysis of ongoing Phase 2B study in rheumatoid arthritis.
Benzinga · 3d ago

Industry

Biotechnology & Medical Research
+1.00%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About SNDX

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, is a once-weekly, oral, small molecule, Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer. The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. It is also developing SNDX-6352, a monoclonal antibody targeting the colony stimulating factor-1 receptor.
More

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.